R&D Center NovaMedica Innotech becomes industrial partner of the Eurasian Academy of Good Practices

17 June 2022

May 17, 2022, Moscow – R&D Center NovaMedica Innotech (subsidiary of the pharma company NovaMedica, RUSNANO portfolio asset) and the independent non-profit organization Eurasian Academy of Good Practices signed the Memorandum of Cooperation aiming to develop competences of the Russian pharmaceutics professionals.

The partners agreed to exchange knowledge and experience in pharmaceutical development and contract manufacturing and to carry out joint training initiatives at the R&D Center NovaMedica Innotech. Besides that, cooperation will involve joint organization of congresses, conferences, round tables and workshops for the professional community, including with international participants.  

Irina SPICHAK, Executive Director of the Eurasian Academy of Good Practices, PhD in Pharmaceutics, Professor:

“In its educational activities, the Academy always relies on a comprehensive approach that provides a good balance between theory and practice. Unique network educational programs give an opportunity to not only use simulation technologies, such as VR Plant, in the practical part of the training, but also to strengthen the knowledge at a real pharmaceutical facility that complies will all GMP requirements. Our students master the theory, while deeply immersing themselves into practice, finding out how to apply what they have learned, and developing the competences that the industry needs”.

Timofey PETROV, Director General of the R&D Center NovaMedica Innotech:

“I am glad that our cooperation will make the pharmaceutical development sphere closer and more understandable for industry specialists. This is another step towards improving the quality of educational programs aimed at professional development of pharmaceutical workers. Students of the Academy from all over the country will learn more about modern R&D capabilities and receive real practical knowledge of state-of-the-art technologies and methods for drug development and manufacturing. In the simple format of master classes they will see specific process solutions and real projects in scaling and manufacturing planning. There is no doubt that it will not only broaden the horizons and improve the qualifications of the specialists participating in the programs, but will also take the Russian manufacturers, whom they represent, to a new level”.

Olga SHPICHKO, Deputy Chair of the Board of Directors of NovaMedica, Managing Director for Investments at RUSNANO Management Company:

“We ardently support integration of the NovaMedica Innotech Center, which is unique in terms of its equipment and competences, in educational programs of the Eurasian Academy of Good Practices. Such unions and partnerships contribute to strengthening of expertise in development and manufacturing of drug products, advancement of pharmaceutics and improvement of drug security in the country. This is absolutely in line with our mission to create infrastructure in the essential Russian industries”.

Parties to the agreement emphasize that they will strive to expand and strengthen their partnership. The Memorandum entered into force at the time of its signing and its validity period is not limited.


Information on the partners:

R&D Center NovaMedica Innotech is a 100% subsidiary of NovaMedica (RUSNANO portfolio asset), Skolkovo resident. NovaMedica Innotech has state-of-the-art technological capabilities and conducts research, development and manufacturing of drugs in full compliance with the GMP standards, including on a contract basis. Manufacturing capacity of the R&D center NovaMedica Innotech is up to 150 million drug units per year (tablets, soft and hard gelatin capsules with various fillers: micro-tablets, pellets, granules, powders).

NovaMedica is a Russian pharmaceutical company created in 2012 by RUSNANO and the US venture fund Domain Associates LLC. NovaMedica’s strategy is aimed at search and localization in Russia of innovative pharmaceutical products and creation of new drugs under its own R&D program. Some of these products already have marketing authorizations. Exclusive rights to manufacturing and commercialization of the first of them, Relifipin, were granted under the partnership agreement to the German pharmaceutical company Bayer. Besides that, NovaMedica has an advanced infrastructure for successful commercialization and promotion of prescription products. See more information at www.novamedica.com

Eurasian Academy of Good Practices (EAGP) is a new educational, science and consultation platform. As the only pharmaceutical academy of the Ministry of Industry and Trade of Russia, the EAGP offers relevant educational programs that meet the current needs of the industry. The Academy also works as a discussion platform for development of regulatory decisions and as an expert center for problematic issues of pharmaceutics. The Academy has a Science and Consultation Center on development and registration of drug products, which employs the most competent experts. As part of its educational activities, the Academy holds top-tier industry contests GxP-Fest for students and teachers of specialized universities, and GxP-Profi for manufacturers of drug products. The EAGP is making an important contribution to providing the industry with qualified personnel, implementing the import substitution program and developing the export potential of pharmaceutical companies.

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more